Form 8-K · Current report
Eli Lilly 8-K, filed Oct 29, 2026
- Filed
- CIK
- 0000059478
- Accession no.
- 0000059478-26-000104
Summary
Eli Lilly reported third-quarter 2026 revenue of $24.4 billion, up 39% year over year on demand for Mounjaro and Zepbound, and raised its full-year 2026 revenue guidance midpoint by $5.5 billion to a range of $91.0–$92.0 billion. The company also cited U.S. FDA approvals including Mounjaro for cardiovascular risk reduction in type 2 diabetes, Onswik as a once-weekly basal insulin, Inluriyo with Verzenio in breast cancer, and an expanded Jaypirca indication, and said CEO David A. Ricks credited broad demand for Mounjaro and Zepbound along with new product launches.
Key points
- Q3 2026 revenue rose 39% to $24.4 billion, with Mounjaro at $10.7 billion (up 65%) and Zepbound at $5.4 billion (up 49%).
- Reported EPS was $7.22 (up 16%) and non-GAAP EPS $7.48 (up 7%), both including $4.57 of acquired IPR&D charges.
- Full-year 2026 revenue guidance midpoint was raised $5.5 billion to $91.0–$92.0 billion; non-GAAP EPS guidance range is $35.00–$36.00.
- Lilly completed the acquisition of AtaiBeckley and, after quarter end, Merida Biosciences, and reported positive Phase 3 head-to-head results for retatrutide versus Ozempic 2 mg in type 2 diabetes.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.